This page summarizes published research on pulsed electromagnetic fields (PEMF) and fibromyalgia. It reports what named studies found and does not state what any device will do for a person with the condition. It is part of ElectroMeds’ PEMF education section, which collects research for reference.
PEMF Fibromyalgia: What researchers have studied
Fibromyalgia research involving PEMF is small and uses markedly different forms of magnetic-field exposure. The published human literature includes brief exposures delivered near the head, multiweek whole-body or broad-area sessions, and a protocol directed to selected body points. Some studies used inactive sham devices and double blinding, while one later pilot was single-blind. Outcomes also vary. Researchers have measured pain ratings, pressure-pain thresholds, fibromyalgia impact, sleep, daily activities, mood, fatigue, and quality-of-life questionnaires.
That variation matters when reading the results. A field strength, waveform, body location, session schedule, sham method, and outcome measure in one trial are not interchangeable with those in another. Most of the direct research enrolled only women, used small samples, and followed participants for weeks rather than months or years. The study record includes both positive and null findings. The studies below are therefore best read as separate investigations of specific research setups, not as evidence that results from one setup transfer to another device format, setting, or person.
The studies
Gikaro et al. (2023) systematic review and network meta-analysis
Gikaro and colleagues systematically searched six databases through March 2023 and evaluated electrophysical-agent research in fibromyalgia. Their qualitative synthesis included 54 studies with 3,045 participants, and their network meta-analysis covered different numbers of studies for pain, function, and mood. The authors’ conclusions identified low- to moderate-quality evidence for certain other modalities, including microcurrent, laser therapy, and repetitive transcranial magnetic stimulation. PEMF was not among the modalities identified in that conclusion as having such evidence.
This review offers a broad map of a mixed field rather than a pooled PEMF estimate. Its included interventions and outcomes were heterogeneous, and its headline results cannot determine the result of a particular PEMF device or format.
Gikaro JM, Bigambo FM, Minde VM, Swai EA. “Efficacy of electrophysical agents in fibromyalgia: A systematic review and network meta-analysis.” Clinical Rehabilitation. 2023;37(10):1295-1310. PMID: 37082791. DOI: 10.1177/02692155231170450.
Shupak et al. (2006)
This double-blind, randomized, placebo-controlled parallel trial examined one acute exposure to a specific pulsed low-frequency magnetic field in women with rheumatoid arthritis or fibromyalgia. The fibromyalgia group comprised 18 women. Participants received either active or sham exposure for 30 minutes. For the fibromyalgia group, the researchers reported a significant pre- to post-exposure effect on the McGill Pain Questionnaire Pain Rating Index and similar findings on pain subcomponents and a visual analogue pain measure. They found no significant pre- to post-exposure reduction in anxiety ratings.
The study evaluated an immediate change after a single exposure, not a sustained outcome. Its small fibromyalgia group and condition-specific apparatus also limit what can be inferred outside that research setting.
Shupak NM, McKay JC, Nielson WR, Rollman GB, Prato FS, Thomas AW. “Exposure to a specific pulsed low-frequency magnetic field: A double-blind placebo-controlled study of effects on pain ratings in rheumatoid arthritis and fibromyalgia patients.” Pain Research & Management. 2006;11(2):85-90. PMID: 16770449. DOI: 10.1155/2006/842162.
Thomas et al. (2007)
Thomas and colleagues conducted a randomized, double-blind, sham-controlled trial in people with either fibromyalgia-related generalized pain or localized musculoskeletal or inflammatory pain. The protocol used a portable head-fitted device over seven days. In the fibromyalgia subgroup of 17 participants, the difference between active and sham pain changes approached, but did not reach, conventional statistical significance (P=0.06). In the 15 participants without fibromyalgia, the corresponding difference was not evident (P=0.93).
The authors explicitly called for a larger trial limited to fibromyalgia. The subgroup was small, the trial combined different pain populations, and the follow-up was only one week. The study does not establish whether its finding applies to other exposure formats or longer periods.
Thomas AW, Graham K, Prato FS, McKay J, Forster PM, Moulin DE, Chari S. “A randomized, double-blind, placebo-controlled clinical trial using a low-frequency magnetic field in the treatment of musculoskeletal chronic pain.” Pain Research & Management. 2007;12(4):249-258. PMID: 18080043. DOI: 10.1155/2007/626072.
Sutbeyaz et al. (2009)
This randomized, double-blind, sham-controlled clinical study assigned 56 women with fibromyalgia to active PEMF or sham exposure, with 28 participants in each group. The study sessions occurred twice daily for three weeks, and assessments were made after treatment and at 12 weeks. At the end of the study period, the active group showed statistically significant improvements in Fibromyalgia Impact Questionnaire scores, visual analogue pain scores, Beck Depression Inventory scores, and all Short Form-36 domains. At follow-up, the improvements in Fibromyalgia Impact Questionnaire, visual analogue pain, and Short Form-36 pain scores were reported as maintained. The sham group also improved on most measures after the study period; at 12 weeks, improvements in Beck Depression Inventory and Short Form-36 scores remained.
This is a stronger design than an uncontrolled report, but it remains one modest-sized trial in women and had only 12 weeks of follow-up. The active and sham groups both changed on several patient-reported measures, which is important context for interpreting between-group findings.
Sutbeyaz ST, Sezer N, Koseoglu F, Kibar S. “Low-frequency pulsed electromagnetic field therapy in fibromyalgia: A randomized, double-blind, sham-controlled clinical study.” The Clinical Journal of Pain. 2009;25(8):722-728. PMID: 19920724. DOI: 10.1097/AJP.0b013e3181a68a6c.
Maestú et al. (2013)
Maestú and colleagues ran a double-blind, randomized, placebo-controlled trial of very low-intensity, transcranial pulsed magnetic stimulation. Fifty-four women completed the study, with 28 in the stimulation group and 26 in the sham group. The researchers evaluated pressure-pain thresholds over eight weekly sessions and also collected symptom questionnaires and blood serotonin measurements. They reported a significantly larger increase in pressure-pain thresholds in the stimulation group across the eight weeks (P=0.01). They also reported significant group-by-time differences for daily activities, sleep quality, and perceived pain. No significant global changes were reported for fatigue, anxiety, depression, headache severity, or serotonin levels.
The protocol was a specialized low-intensity transcranial setup, not a general description of PEMF formats. Participants had restrictions on concurrent medication, outcomes were largely short-term, and no extended post-study follow-up was reported.
Maestú C, Blanco M, Nevado A, Romero J, Rodríguez-Rubio P, Galindo J, Lorite JB, de las Morenas F, Fernández-Argüelles P. “Reduction of pain thresholds in fibromyalgia after very low-intensity magnetic stimulation: A double-blinded, randomized placebo-controlled clinical trial.” Pain Research & Management. 2013;18(6):e101-e106. PMID: 24308025. DOI: 10.1155/2013/270183.
Multanen et al. (2018)
Multanen and colleagues reported a randomized controlled study of low-energy PEMF in women with fibromyalgia. The published record identifies the study as randomized and PubMed indexes it as double-blind and cross-over. The authors concluded that their low-energy PEMF setup was no more effective than sham for pain, stiffness, or functioning. This null result is a necessary part of the direct fibromyalgia record.
The PubMed abstract supplies little numeric outcome detail, so its result should not be overread in either direction. As with the other trials, its device-specific setup, study population, and limited published detail constrain comparison with other formats.
Multanen J, Häkkinen A, Heikkinen P, Kautiainen H, Mustalampi S, Ylinen J. “Pulsed electromagnetic field therapy in the treatment of pain and other symptoms in fibromyalgia: A randomized controlled study.” Bioelectromagnetics. 2018;39(5):405-413. PMID: 29709070. DOI: 10.1002/bem.22127.
Giovale et al. (2022)
This single-center, randomized, single-blind controlled pilot study enrolled 21 women with fibromyalgia. Researchers compared a low-energy PEMF protocol directed to selected target points with placebo and assessed participants at baseline, four weeks, and eight weeks. The active group had a statistically larger reduction in widespread pain index, symptom-severity score, and visual analogue pain score than the placebo group. The groups also differed numerically on Fibromyalgia Impact Questionnaire and Short Form-36 results, but those differences did not reach statistical significance.
As a pilot, the study was very small and only single-blind. Its point-directed protocol, medication restrictions, and eight-week observation period further limit generalizability. The statistically nonsignificant function and quality-of-life findings should remain part of the interpretation.
Giovale M, Novelli L, Persico L, Motta F, Rampoldi S, Galli R, Monteforte P, Doveri M, Bianchi G, Selmi C, Bottaro LC. “Low-energy pulsed electromagnetic field therapy reduces pain in fibromyalgia: A randomized single-blind controlled pilot study.” Rheumatology and Immunology Research. 2022;3(2):77-83. PMID: 36465321. DOI: 10.2478/rir-2022-0013.
How strong is this evidence?
The direct evidence is limited and mixed. It includes several randomized, sham-controlled studies, which is a useful safeguard against expectation effects, but the individual trials are small. The direct fibromyalgia samples ranged from 17 in the Thomas subgroup to 56 in the Sutbeyaz trial, and the 2022 pilot enrolled 21 women. Such samples can produce uncertain estimates and make results difficult to reproduce. They also narrow generalizability, since the available trials largely enrolled women and were conducted in particular clinical settings.
The interventions are not one consistent exposure. Shupak studied a one-time exposure; Thomas used a head-fitted setup; Sutbeyaz described a multiweek course; Maestú used very low-intensity transcranial stimulation; Giovale used selected target points; and Multanen evaluated a different low-energy system. Differences in apparatus, body location, field characteristics, schedules, sham procedures, and outcome measures make pooling the findings into one device-level conclusion inappropriate.
Results also conflict. Sutbeyaz, Maestú, and Giovale each reported some statistically significant findings, while Thomas had a fibromyalgia subgroup result that did not reach conventional statistical significance and Multanen reported no advantage over sham for its primary symptom outcomes. Relevant null results appeared within positive studies as well, including Maestú’s fatigue, anxiety, depression, headache, and serotonin measures and Giovale’s Fibromyalgia Impact Questionnaire and Short Form-36 comparisons. Follow-up ranged from immediate post-exposure assessment to 12 weeks. There is no large, independently replicated body of long-term research that establishes whether any study result applies to a retail PEMF device.
What this means if you are considering a PEMF device
Fibromyalgia is associated with widespread symptoms, so a full-body mat or another broad-area format is the closest format comparison when looking at studies that used whole-body or broad exposure. A local applicator has a different format relationship to that research. The studies also included head-fitted, transcranial, and point-directed setups. These differences matter because the published protocols were specific to their research settings.
A device listing may describe format, controls, accessories, field specifications, warranty, and return terms. Those details can help distinguish what is being offered, but they do not show that the device reproduces any study’s apparatus, settings, participant selection, or outcomes. The research above is not a buying recommendation or a substitute for clinical care. For background on formats and comparisons, see PEMF mat versus PEMF machine and how to choose a PEMF device.
Questions to ask before buying
- Is the format a full-body mat, a broad-area applicator, or a local applicator?
- Does the seller provide the device’s field specifications and operating documentation in writing?
- What accessories, controls, and replacement parts are included in the listed price?
- What are the warranty length, return window, shipping costs, and restocking terms?
- Who provides customer support, and how are repairs or returns handled?
- Can the seller clearly distinguish product information from summaries of published research?
This page summarizes published research for reference. It is not medical advice, and nothing here is a claim that any PEMF device treats, cures, or prevents any condition. PEMF is not appropriate for everyone — review PEMF contraindications and talk with your own physician before beginning any new therapy, particularly if you have an implanted electronic device, are pregnant, or are being treated for a serious medical condition.